scholarly journals Fibrosis and Subsequent Cytopenias Are Associated with Basic Fibroblast Growth Factor–Deficient Pluripotent Mesenchymal Stromal Cells in Large Granular Lymphocyte Leukemia

2013 ◽  
Vol 191 (7) ◽  
pp. 3578-3593 ◽  
Author(s):  
Adam W. Mailloux ◽  
Ling Zhang ◽  
Lynn Moscinski ◽  
John M. Bennett ◽  
Lili Yang ◽  
...  
2017 ◽  
Vol 6 (10) ◽  
pp. 1880-1893 ◽  
Author(s):  
Hongliang Zhang ◽  
Alexander Kot ◽  
Yu-An E. Lay ◽  
Fernando A. Fierro ◽  
Haiyan Chen ◽  
...  

1996 ◽  
Vol 151 (2) ◽  
pp. 315-322 ◽  
Author(s):  
A T Collins ◽  
E J Robinson ◽  
D E Neal

Abstract The current study was undertaken, using cultures of prostatic epithelial and stromal cells, to determine the functional interactions between androgens, basic fibroblast growth factor (FGF2) and transforming growth factor-β1 (TGFβ1) and their importance in maintaining stromal homeostasis. Treatment of stromal cells with TGFβ1 significantly increased intracellular FGF2 and FGF2 sequestered to the extracellular matrix. FGF2 was also detected in stromal conditioned medium (SCM), but at levels 70-fold less than found in cell lysates. TGFβ1 (0·1 ng/ml) treatment caused an initial increase of 86% in secreted FGF2 levels, but high concentrations of TGFβ1 (5 ng/ml) decreased FGF2 levels by 38%, relative to the untreated control. Further studies showed that epithelial conditioned medium (ECM), androgen-treated, stromal conditioned medium (ASCM), but not SCM were mitogenic for stromal cells. Both ECM and ASCM caused a threefold increase in DNA synthesis. FGF2 may be the mediator of these interactions, since the mitogenic effect of both ECM and ASCM was significantly reduced by the addition of anti-FGF2 neutralising antibody. We hypothesise that the lack of response of stromal cells to SCM is due to TGFβ1 blocking the mitogenic effect of FGF2. Thus down-regulation of TGFβ1 synthesis, by androgens, results in stromal proliferation by ASCM. Journal of Endocrinology (1996) 151, 315–322


2017 ◽  
Vol 2017 ◽  
pp. 1-22 ◽  
Author(s):  
Daria Nawrocka ◽  
Katarzyna Kornicka ◽  
Joanna Szydlarska ◽  
Krzysztof Marycz

Type 2 diabetes (T2D) is a chronic metabolic disorder affecting increasing number of people in developed countries. Therefore new strategies for treatment of T2D and its complications are of special interest. Nowadays, cellular therapies involving mesenchymal stromal cells that reside in adipose tissue (ASCs) constitute a promising approach; however, there are still many obstacles concerning safety and effectiveness that need to be overcome before ASCs could be engaged for the treatment of diabetes mellitus. One of the challenges is preventing ASCs from deterioration caused by elevated oxidative stress present in diabetes milieu. In the current study we investigated the effect of basic fibroblast growth factor (bFGF) treatment on ASCs isolated from patients with diagnosed T2D. We demonstrate here that cell exposition to bFGF in 5 and 10 ng/mL dosages results in improved morphology, increased proliferative activity, reduced cellular senescence and apoptosis, and decreased oxidative stress, indicating recovery of ASCs’ function impaired by T2D. Therefore our results provide a support for bFGF as a potential therapeutic agent for improving stem cell-based approaches for the treatment of diabetes mellitus and its complications.


Sign in / Sign up

Export Citation Format

Share Document